Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 103


Anticoagulation in children: Making the most of little patients and little evidence.

Young G, Male C, van Ommen CH.

Blood Cells Mol Dis. 2017 May 6. pii: S1079-9796(16)30246-7. doi: 10.1016/j.bcmd.2017.05.003. [Epub ahead of print]


Intensity of factor VIII treatment and the development of inhibitors in non-severe hemophilia A patients: results of the INSIGHT case-control study.

van Velzen AS, Eckhardt CL, Peters M, Leebeek FWG, Escuriola-Ettingshausen C, Hermans C, Keenan R, Astermark J, Male C, Peerlinck K, le Cessie S, van der Bom JG, Fijnvandraat K.

J Thromb Haemost. 2017 Jul;15(7):1422-1429. doi: 10.1111/jth.13711. Epub 2017 Jun 2.


Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.

Cannavò A, Valsecchi C, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, Peyvandi F; SIPPET study group.

Blood. 2017 Mar 9;129(10):1245-1250. doi: 10.1182/blood-2016-06-720086. Epub 2016 Dec 29. Erratum in: Blood. 2017 Jul 13;130(2):232.


Anti-activated factor II assay for monitoring unfractionated heparin in children: results of the HEARTCAT study.

Hanslik A, Kitzmüller E, Tran US, Thom K, Karapetian H, Prutsch N, Voitl J, Michel-Behnke I, Newall F, Male C.

J Thromb Haemost. 2017 Jan;15(1):38-46. doi: 10.1111/jth.13539. Epub 2016 Nov 25.


Long-acting recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in children. Results of a phase 3 trial.

Kenet G, Chambost H, Male C, Lambert T, Halimeh S, Chernova T, Mancuso ME, Curtin J, Voigt C, Li Y, Jacobs I, Santagostino E; PROLONG-9FP Investigator Study Group.

Thromb Haemost. 2016 Sep 27;116(4):659-68. doi: 10.1160/TH16-03-0179. Epub 2016 Sep 1.


Directions for new developments on statistical design and analysis of small population group trials.

Hilgers RD, Roes K, Stallard N; IDeAl, Asterix and InSPiRe project groups.

Orphanet J Rare Dis. 2016 Jun 14;11(1):78. doi: 10.1186/s13023-016-0464-5.


A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.

Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Hanagavadi S, Varadarajan R, Karimi M, Manglani MV, Ross C, Young G, Seth T, Apte S, Nayak DM, Santagostino E, Mancuso ME, Sandoval Gonzalez AC, Mahlangu JN, Bonanad Boix S, Cerqueira M, Ewing NP, Male C, Owaidah T, Soto Arellano V, Kobrinsky NL, Majumdar S, Perez Garrido R, Sachdeva A, Simpson M, Thomas M, Zanon E, Antmen B, Kavakli K, Manco-Johnson MJ, Martinez M, Marzouka E, Mazzucconi MG, Neme D, Palomo Bravo A, Paredes Aguilera R, Prezotti A, Schmitt K, Wicklund BM, Zulfikar B, Rosendaal FR.

N Engl J Med. 2016 May 26;374(21):2054-64. doi: 10.1056/NEJMoa1516437.


Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.

Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulsom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team.

J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.


Evidence, eminence and extrapolation.

Hlavin G, Koenig F, Male C, Posch M, Bauer P.

Stat Med. 2016 Jun 15;35(13):2117-32. doi: 10.1002/sim.6865. Epub 2016 Jan 11.


The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.

van Velzen AS, Eckhardt CL, Streefkerk N, Peters M, Hart DP, Hamulyak K, Klamroth R, Meijer K, Nijziel M, Schinco P, Yee TT, van der Bom JG, Fijnvandraat K; INSIGHT study group.

Thromb Haemost. 2016 Mar;115(3):543-50. doi: 10.1160/TH15-03-0212. Epub 2015 Nov 19.


[Treatment of haemophilia in Austria].

Pabinger I, Heistinger M, Muntean W, Reitter-Pfoertner SE, Rosenlechner S, Schindl T, Schuster G, Streif W, Thom K, Male C.

Wien Klin Wochenschr. 2015 Nov;127 Suppl 3:S115-30. doi: 10.1007/s00508-015-0872-x. Epub 2015 Nov 2. German.


Inhibitor development in non-severe haemophilia across Europe.

Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Hollingsworth R, Makris M; EUHASS Participants.

Thromb Haemost. 2015 Oct;114(4):670-5. doi: 10.1160/TH14-12-1044. Epub 2015 Aug 13. Erratum in: Thromb Haemost. 2016 Mar;115(3):684. Hollingsworth, R [Added].


Monitoring unfractionated heparin in children: a parallel-cohort randomized controlled trial comparing 2 dose protocols.

Hanslik A, Kitzmüller E, Tran US, Thom K, Karapetian H, Prutsch N, Voitl J, Michel-Behnke I, Newall F, Male C.

Blood. 2015 Oct 29;126(18):2091-7. doi: 10.1182/blood-2015-06-651661. Epub 2015 Aug 3.


FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies.

Fischer K, Iorio A, Hollingsworth R, Makris M; EUHASS collaborators.

Haemophilia. 2016 Jan;22(1):e36-8. doi: 10.1111/hae.12764. Epub 2015 Jul 24. No abstract available.


The EPIC study: a lesson to learn.

Auerswald G, Kurnik K, Aledort LM, Chehadeh H, Loew-Baselli A, Steinitz K, Reininger AJ; EPIC clinical study group.

Haemophilia. 2015 Sep;21(5):622-8. doi: 10.1111/hae.12666. Epub 2015 Apr 23.


Inhibitor development and mortality in non-severe hemophilia A.

Eckhardt CL, Loomans JI, van Velzen AS, Peters M, Mauser-Bunschoten EP, Schwaab R, Mazzucconi MG, Tagliaferri A, Siegmund B, Reitter-Pfoertner SE, van der Bom JG, Fijnvandraat K; INSIGHT Study Group.

J Thromb Haemost. 2015 Jul;13(7):1217-25. doi: 10.1111/jth.12990. Epub 2015 Jun 10.


Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans.

Hofbauer CJ, Whelan SF, Hirschler M, Allacher P, Horling FM, Lawo JP, Oldenburg J, Tiede A, Male C, Windyga J, Greinacher A, Knöbl PN, Schrenk G, Koehn J, Scheiflinger F, Reipert BM.

Blood. 2015 Feb 12;125(7):1180-8. doi: 10.1182/blood-2014-09-598268. Epub 2014 Dec 16.


Central venous catheter-related thrombosis and thromboprophylaxis in children: a systematic review and meta-analysis: discussion.

Male C, O'Brien S, Rodriguez V, Mitchell LG.

J Thromb Haemost. 2015 Apr;13(4):688-90. doi: 10.1111/jth.12818. Epub 2015 Feb 4. No abstract available.


Recommendations for the development of new anticoagulant drugs for pediatric use: communication from the SSC of the ISTH.

Male C, Monagle P, Chan AK, Young G; Pediatric/Neonatal Hemostasis and Thrombosis Scientific and Standardization Subcommittee of the International Society on Thrombosis and Haemostasis.

J Thromb Haemost. 2015 Mar;13(3):481-4. doi: 10.1111/jth.12807. Epub 2015 Jan 7. Review. No abstract available.


No impact of endogenous prothrombotic conditions on the risk of central venous line-related thrombotic events in children: results of the KIDCAT study (KIDs with Catheter Associated Thrombosis).

Thom K, Male C, Mannhalter C, Quehenberger P, Mlczoch E, Luckner D, Marx M, Hanslik A.

J Thromb Haemost. 2014 Oct;12(10):1610-5. doi: 10.1111/jth.12699. Epub 2014 Sep 22. Erratum in: J Thromb Haemost. 2014 Nov;12(11):1949.

Supplemental Content

Loading ...
Support Center